Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Twist Bioscience Corp (NQ: TWST )

27.55 +0.57 (+2.11%)
Streaming Delayed Price Updated: 12:51 PM EST, Dec 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Twist Bioscience Corp

< Previous 1 2 3 4 5 6 7 Next >
Twist Bioscience Corp. (NASDAQ: TWST) Near the Top of Equities by Percentage Gain on 11/17
Via Investor Brand Network
Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2023 Financial Results
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches Express Genes Rapid Gene Synthesis Service
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at 6th Annual Evercore ISI HealthCONx Conference
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Report Fiscal 2023 Fourth Quarter and Full Year Financial Results on Friday, November 17, 2023
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches Full Length Unique Dual Index Adapters to Enable PCR-free Whole Genome Sequencing
From Twist Bioscience Corporation
Via Business Wire
TWIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Twist Bioscience Corp on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Twist Bioscience Enters into Antibody Discovery and Licensing Option Agreement with Bayer of up to $188 Million
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Appoints Mark Buck as Senior Vice President, Operations
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience and IMIDomics Collaborate to Discover Antibodies for Applications in Immune-Mediated Inflammatory Diseases
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at Upcoming Investor Conferences
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Releases 2023 ESG Report and Quantifies Carbon Footprint of Manufacturing a Single Gene
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at the UBS MedTech, Tools and Genomics Summit 2023
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Reports Fiscal Third Quarter 2023 Financial Results
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Report Fiscal 2023 Third Quarter Financial Results on Friday, August 4, 2023
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience and Cancer Research Horizons Enter into Collaboration to Advance Cancer Research
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Publishes Preclinical Data in Diabetes Validating GLP-1R Antagonist Antibody as Potential Treatment for Congenital Hyperinsulinism
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Appoints Chet Gandhi as Chief Information Officer
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience and CeGaT Launch RNA Fusion Panel to Advance Oncology and Precision Medicine Research
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at Upcoming Investor Conferences
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Appoints Robert Werner as Chief Accounting Officer
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches Portfolio of RNA Sequencing Tools
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at ITF World 2023
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Reports Fiscal Second Quarter 2023 Financial Results
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience and Aster Insights Partner on Launch of Next Generation Oncology Panel for Cancer Research
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Enters into Third Collaboration with Astellas to Support Antibody Discovery for Immunotherapies
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches TCR and CAR Libraries to Enable the Development of Cell Therapies
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Report Fiscal 2023 Second Quarter Financial Results on Friday, May 5, 2023
From Twist Bioscience Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.